ANI Pharmaceuticals Inc (ANIP)vsHaleon plc (HLN)
ANIP
ANI Pharmaceuticals Inc
$74.07
+1.04%
HEALTHCARE · Cap: $1.66B
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1149% more annual revenue ($11.03B vs $883.37M). HLN leads profitability with a 15.1% profit margin vs 8.9%. ANIP appears more attractively valued with a PEG of 1.06. HLN earns a higher WallStSmart Score of 58/100 (C).
ANIP
Buy57
out of 100
Grade: C
HLN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-237.7%
Fair Value
$22.58
Current Price
$74.07
$51.49 premium
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 29.6% year-over-year
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 16.9%
Distress zone — elevated risk
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIP
The strongest argument for ANIP centers on Price/Book, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : ANIP
The primary concerns for ANIP are Market Cap, Piotroski F-Score, EPS Growth.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ANIP profiles as a growth stock while HLN is a value play — different risk/reward profiles.
ANIP carries more volatility with a beta of 0.46 — expect wider price swings.
ANIP is growing revenue faster at 29.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 57/100), backed by strong 15.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?